Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accumulated Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Accumulated Expenses for 4 consecutive years, with $54.6 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 20.42% year-over-year to $54.6 million; the TTM value through Dec 2025 reached $54.6 million, down 20.42%, while the annual FY2025 figure was $54.6 million, 20.42% down from the prior year.
  • Accumulated Expenses was $54.6 million for Q4 2025 at Day One Biopharmaceuticals, up from $48.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $87.1 million in Q2 2024, with the low at $7.3 million in Q1 2022.
  • Historically, Accumulated Expenses has averaged $33.7 million across 4 years, with a median of $25.6 million in 2023.
  • The largest annual shift saw Accumulated Expenses surged 346.09% in 2024 before it plummeted 49.32% in 2025.
  • Over 4 years, Accumulated Expenses stood at $16.0 million in 2022, then soared by 66.29% to $26.5 million in 2023, then surged by 158.73% to $68.6 million in 2024, then dropped by 20.42% to $54.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $54.6 million in Q4 2025, $48.2 million in Q3 2025, and $44.1 million in Q2 2025.